To the editor
=============

Inflammatory breast cancer (IBC) is a rare and aggressive clinical form of BC representing less than 2% of all BC in westerns countries. However, in North Africa, the incidence of IBC is higher accounting for more than 5% of all BC. It is diagnosed clinically by the rapid onset of diffuse erythema and edema (peau d'orange) of at least a third of the skin overlying the breast that rapidly extends to the entire breast. IBC appears to behave as an ER-negative subtype and HER2-positive subtype. In addition, studies of molecular biology identified several anomalies such as EGFR1 over-expression. Considering cell-of-origin subtypes, most cases of IBC belong to the basal, the luminal-B, or the HER2-overexpressing subtype. The treatment of this disease has evolved significantly during the past three decades, incorporating combined modality; chemotherapy, surgery and radiotherapy. The 5- and 10-year overall survival rate was 56% and 35%, respectively for patients who have received multimodal therapy \[[@B1]-[@B4]\].

From 1800 patients having the diagnosis of BC registered at the National Institute of Oncology of Rabat between January 2007 and December 2008, we identified 90 patients (5% of BC) diagnosed (according to the international criteria) with IBC. Table [1](#T1){ref-type="table"} analyzes patient characteristics and outcomes. In our study, we included 72 patients with nonmetastatic IBC. The median age of patients was 47 years and the dominant histology was infiltrating ductal carcinoma (96%). Most patients had high nuclear grade II/III (77.8%), 43.4% \[23/53\] were ER-negative and 47.4% \[18/38\] were HER2-postive on IHC. Only 48.6% of the patients received completed treatment (CT, surgery, and RT). All patients received anthracycline neoadjuvant CT, 37 (51.4%) received Taxane and one received Trastuzumab. Fifty one patients (71% of the cases) underwent surgery (mastectomy) and 54% received RT.

###### 

Patient characteristics and outcomes

  **Characteristics**                      **All patients (n = 90) 5% of all breast cancers (n = 1800)**   **Patients with nonmetastatic disease (n = 72)**
  --------------------------------------- --------------------------------------------------------------- --------------------------------------------------
  Patient's characteristics                                                                                                        
  Age                                                                                                                              
    Median                                                              47                                                        47
    Range                                                             29 - 75                                                  29 - 75
  Menoposal status                                                                                                                 
    Premenoposal                                                    51 (56.7%)                                                 38 (53%)
    Postmenoposal                                                   34 (37.8%)                                                    30
    Unknown                                                              5                                                        4
  Histilogy                                                                                                                        
    Infiltrating ductal carcinoma                                   84 (93.3%)                                                 69 (96%)
    Infiltrating lobular carcinoma                                   3 (3.3%)                                                     2
    Other                                                            3 (3.3%)                                                     3
  SBR                                                                                                                              
    I                                                                5 (5.6%)                                                     4
    II                                                               45 (50%)                                                     36
    III                                                             24 (26.7%)                                                    20
    Unknown                                                         16 (17.7%)                                                    12
  Hormone receptor status                                                                                                          
    ER+/PR+                                                             37                                                        30
    ER+/PR-                                                              0                                                        0
    ER-/PR+                                                             23                                                    19 (26.4%)
    ER-/PR-                                                              4                                                     4 (5.6%)
    Unknown                                                             26                                                        19
  HER2/neu status                                                                                                                  
    Positif                                                         23 (25.5%)                                                 18 (25%)
    Negatif                                                             22                                                        20
    Unknown                                                             45                                                        34
  Clinical stage N                                                                                                                 
    N0                                                              31 (34.4%)                                                 23 (32%)
    N1                                                              42 (46.7%)                                                    33
    N2                                                              12 (13.3%)                                                    12
    N3                                                               5 (5.6%)                                                     4
  Clinical stage M                                                                                                                 
    M0                                                               72 (80%)                                                     72
    M1                                                               18 (20%)                                                     0
  Taxanes                                                                                                                          
    Yes                                                                 45                                                    37 (51.4%)
    No                                                                  43                                                    35 (48.6%)
    Unknown                                                              2                                                        0
  Surgery                                                                                                                          
    Yes                                                                 53                                                     51 (71%)
    No                                                                  37                                                     21 (29%)
  Radiotherapy                                                                                                                     
    Yes                                                                 40                                                     39 (54%)
    No                                                                  50                                                     33 (36%)
    cOR (CR + PR)                                                       \-                                                     49 (68%)
    pCR                                                                 \-                                                     1 (1.4%)
    Pathologically negative lymph nodes                                                                                         5 (7%)
    1 and 2 y LRRFS                                                     \-                                                   90.8%; 78.1%
    1 and 2 y EFS                                                       \-                                                   81.7%; 57.5%
    1 and 2 y OS                                                        \-                                                   94.3%; 74.6%

Outcomes of our patients are poor in concordance with a recent American study \[[@B5]\]; cOR was 68% and only 1 (1.4%) patient had pCR in the breast and 5 (7%) in lymph nodes. At 15 months median follow-up, LRRFS, EFS and OS rates at 1--2 years were 90.8%-78.1%, 81.7%-57.5%, and 94.3%-74.6%, respectively (Figures [1](#F1){ref-type="fig"}A, B, and C, respectively). Patients with ER-negative tumors had worse prognosis than patients with ER + tumors; the difference in EFS between the two groups was statistically significant (P = 0.043) (Figure [1](#F1){ref-type="fig"}D). RT was associated with significant increase of LRRFS, EFS and OS (P \< 0.0001, P \< 0.001 and P = 0.017, respectively) (Figures [1](#F1){ref-type="fig"}E, F and G). These data confirmed the higher impact of RT in the management of this aggressive disease. In addition, others factors have been demonstrated to influence survival in patients with IBC according to the most powered investigations, such as menopausal status, nuclear grade, lymphovascular invasion, surgical margins and Trastuzumab \[[@B6]-[@B11]\]. We analyzed the impact of these factors on the outcomes of IBC patients; however, due to the limited statistical power of the cohort, no other significant factors were identified. Only 35 patients had the determination of the HR status and the HER2 status. Kaplan Meier curves showed that ER+/HER2- and ER+/HER2+ patients had better outcome than ER-/HER2+ and ER-/HER2- patients, however the difference was not significant (P = 0.3) (Figure [1](#F1){ref-type="fig"}H).

![**The figure below shows the outcomes of nonmetastatic IBC in Morocco (A, B and C), the prognostic factors (D, E, F and G) and the impact of molecular subtypes (H). A**: LRRFS probability in nonmetastatic IBC patients; **B**: EFS probability in nonmetastatic IBC patients; **C**: OS probability in nonmetastatic IBC patients; **D**: Positive effect of ER-positive status in EFS; **E**: Positive impact of RT in LRRFS; **F**: Positive impact of RT in EFS; **G**: Positive impact of RT in OS; **H**: Survival according to molecular subtypes.](2162-3619-3-1-1){#F1}
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